Brian J. Brille, Vice Chairman at Caris Life Sciences, shared a post on LinkedIn:
“Caris Life Sciences (NASDAQ: CAI) today announced that our therapeutic research arm, Caris Discovery, entered into a multi-year collaboration and license agreement with Genentech, a member of the Roche Group. We will work to identify and validate novel oncology targets in solid tumor tissue.
Caris Life Sciences is eligible to receive upfront and near-term payments of $25 million and is also eligible for up to $1.1 billion of potential research, development, commercial and net sales milestone payments, as well as potential tiered royalties on net sales of collaboration therapies.
We are able to leverage insights from our extensive repository of ~500,000 solid tumor samples, along with matched comprehensive molecular and clinical data, to offer sophisticated and flexible target discovery capabilities leveraging both tissue-based and data-centric techniques to biopharma partners. Caris Discovery scientists use an integrated bioinformatics and wet-lab workflow, which combines interrogation of solid tissue and cell-based systems with multimodal data to validate prioritized targets and help advance the development of next generation therapies.
Caris Life Sciences Announces Collaboration with Genentech to Discover Novel Therapeutic Targets in Cancers with High Unmet Clinical Needprnewswire.com”
More posts about Caris Life Sciences.